DEVELOPING NEW PLATFORM FOR ANTI EGFR ANTICANCER DRUG TESTING
Ewelina Stoczyńska-Fidelus, Marcin Jankiewicz, Cezary Tręda, Maciej Walczak, Marta Winiecka, Sylwester Piaskowski, Krystyna Hułas-Bigoszewska, Piotr Rieske, Dawid Grzela
Celther Polska Sp. z o. o.
Milionowa street 23; 90-364 Łódź, Poland
Many of anti EGFR small molecules can not be easily tested in vitro. One of the examples are compounds designed against EGFRvIII. So far cells lines showing EGFRvIII have to be genetically engineered. Cancer cells spontaneously showing this alterations in vivo are extremely difficult to be cultured in vitro. To this end, we develop new platform for anti EGFRvIII in vitro drug testing. Several new molecular biology tools and cell biology approaches are considered. Typical EGFRvIII expression plasmids were constructed as well as viral vectors. Moreover, EGFRvIII was fused with tags proteins such as venus to trace this protein effects in real time. Those genetically engineered tools were tested in traditional and new cell culture observation systems. Several breast and prostate cancer cells lines showing EGFRvIII were developed. Our results suggest answer for question why cells showing EGFRvIII are so difficult subject of in vitro drug testing. It offers new information about conditions for their cell culture. New models of in vitro anti EGFRvIII drugs testing are under construction.
This work was supported by Polish Agency for Enterprise Development UDA-POIG.01.04.00-10-012/11-00.